7.67
0.03 (0.39%)
| Penutupan Terdahulu | 7.64 |
| Buka | 7.69 |
| Jumlah Dagangan | 490,486 |
| Purata Dagangan (3B) | 761,034 |
| Modal Pasaran | 800,697,408 |
| Harga / Jualan (P/S) | 25.12 |
| Harga / Buku (P/B) | 2.08 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 Nov 2025 |
| Margin Operasi (TTM) | -583.86% |
| EPS Cair (TTM) | -11.24 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 18.94% |
| Nisbah Semasa (MRQ) | 3.73 |
| Aliran Tunai Operasi (OCF TTM) | -291.17 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -169.99 M |
| Pulangan Atas Aset (ROA TTM) | -101.07% |
| Pulangan Atas Ekuiti (ROE TTM) | -247.04% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Alumis Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -2.0 |
| Aktiviti Orang Dalam | 3.5 |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | -0.20 |
|
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 0.63% |
| % Dimiliki oleh Institusi | 53.94% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Ayurmaya Capital Management Company, Lp | 30 Sep 2025 | 15,139,706 |
| Foresite Capital Management V, Llc | 30 Sep 2025 | 5,779,348 |
| Trium Capital Llp | 30 Sep 2025 | 3,122,111 |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| FORESITE CAPITAL MANAGEMENT VI LLC | 7.30 | - | 72,212 | 527,148 |
| FORESITE LABS, LLC | 7.30 | - | 72,212 | 527,148 |
| TANANBAUM JAMES B. | 7.30 | - | 72,212 | 527,148 |
| Jumlah Keseluruhan Kuantiti Bersih | 216,636 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 1,581,443 | |||
| Purata Pembelian Keseluruhan ($) | 7.30 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| FORESITE LABS, LLC | 21 Nov 2025 | Beli (+) | 72,212 | 7.30 | 527,148 | |
| TANANBAUM JAMES B. | Pengarah | 21 Nov 2025 | Beli (+) | 72,212 | 7.30 | 527,148 |
| FORESITE CAPITAL MANAGEMENT VI LLC | 21 Nov 2025 | Beli (+) | 72,212 | 7.30 | 527,148 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 13 Nov 2025 | Pengumuman | Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress |
| 04 Nov 2025 | Pengumuman | Alumis to Participate in Upcoming November Investor Conferences |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |